Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
about
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort StudyEfficacy and safety of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C in persons with sickle cell disease.Shortening the duration of therapy for chronic hepatitis C infection.Interferon-free therapies for patients with chronic hepatitis C genotype 3 infection: A systematic review.Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment.Eight- or 12-Week Treatment of Hepatitis C with Ledipasvir/Sofosbuvir: Real-World Experience in a Large Integrated Health System.Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience.Racial Disparity in Gastrointestinal Cancer Risk.Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.Real-World Effectiveness of DAA Therapies in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection: 996 Veterans Can't Be Wrong.Baseline NS5A Resistance Associated Substitutions May Impair DAA Response in Real-World Hepatitis C Patients.Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient.Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: a retrospective cohort study.Efficacy and Safety of Direct-acting Antivirals in Hepatitis C Virus-infected Patients Taking Proton Pump Inhibitors.Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.Predictors Associated with Increase in Skeletal Muscle Mass after Sustained Virological Response in Chronic Hepatitis C Treated with Direct Acting Antivirals.Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients with Genotype 1 Hepatitis C Virus Infection and Cirrhosis.Real-world treatment of hepatitis C with second-generation direct-acting antivirals: initial results from a multicentre Canadian retrospective cohort of diverse patients.Transporter expression in non-cancerous and cancerous liver tissue from donors with hepatocellular carcinoma and chronic hepatitis C infection quantified by LC-MS/MS proteomics.Noninvasive Assessment of Fibrosis Regression in Hepatitis C Virus Sustained Virologic Responders.All-oral DAA therapy against HCV in HIV/HCV-coinfected subjects in real-world practice: Madrid-CoRe Findings.Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection.HEPATOCELLULAR CARCINOMA: DIAGNOSIS AND OPERATIVE MANAGEMENT.Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing.According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1low HCV-Specific CD8+ Cell Reactivity.Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments.Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy.Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection.Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study.The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir.Treatment of Hepatitis C Virus (HCV) Genotype 1 Disease.Daclatasvir and sofosbuvir treatment of decompensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real-world cohort.Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy.Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance.Real-world Efficacy of Direct-Acting Antiviral Therapy for HCV Infection Affecting People Who Inject Drugs Delivered in a Multidisciplinary Setting.Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis CHepatitis C Virus Clearance by Direct-acting Antiviral Results in Rapid Resolution of Hepatocytic Injury as Indicated by Both Alanine Aminotransferase and Aspartate Aminotransferase Normalization
P2860
Q31168033-0252E64C-4B5D-492D-AE99-E8C2A9FEC194Q38402939-373AB449-EC3B-49A9-BA51-3DBFD04993C8Q38627508-3D416E25-5449-42C9-BB37-50ECF898E0D7Q38786225-EAB92F2A-8D62-428D-9478-FC3931083740Q38876302-9FE0FF68-1774-45D5-A5FE-0E3837129663Q39025640-413ECADF-5A17-4A50-ABB9-91A2F3605854Q39058953-7079CC8F-E740-4F7A-B6EB-A55C1E6ED3A2Q39289372-EF772294-6711-4555-895C-4E7A2CD1ABF4Q40083252-2D879E6B-387D-4B64-AE21-983A017EDAD7Q40129813-3F86C8D5-A3EA-4B3B-B15B-401F847A57B5Q40335100-D2B13AF4-0C3F-4054-B0A7-A152386D343CQ40335115-F70DD325-B5F0-41B4-9E14-1805C7278805Q41921724-28AE3857-8C2F-4E9E-9524-24666DD2B154Q42663239-8EC0E7F6-6EC9-4076-AA63-3EA9A227157DQ44297171-477E54F0-1B40-4E3E-97E6-22D53C42D6FCQ45323549-4C4FD2BE-3AFF-4D57-8359-DAED819734A8Q45325427-F97C03AF-41C7-4369-829E-208EB6C7A2CBQ45372289-B9AB38D9-B319-43BE-83C8-383B4E1D1701Q47202796-85D43DD6-E835-43CB-B003-4FDD1E532622Q47203653-A1358A64-4399-4218-9EB2-3012D702CA59Q47402203-8C0F1CC3-0364-471F-8BCB-10C685B945ABQ47546971-55D34134-EAA4-46DE-B8CA-7A3C35627A6CQ47548361-F90330C1-1705-40EB-AFB3-2B17B73EB35DQ47548651-86CA52C5-F5AF-4AAD-A151-9E51956EF7AFQ47552666-21DF024A-137E-44BA-9DEA-D07084AB9A7DQ47565629-72EC8C0F-7C4B-42B6-BC16-C20F4C976D37Q47587162-4A2467CD-8B66-4352-B1CF-729065D34453Q47593614-E5BD92AA-16B3-423A-8FAA-C1B2CF6D50B0Q47595176-67E61D6C-1080-41CC-BCAB-1C7862B2A7E1Q49823266-BCE0DD48-B5FF-49A6-B4D6-4629F6D9049FQ49911983-F76A6BF3-7FC4-4981-987E-6E5A44B3FD2AQ52594744-5DCB5430-586F-40CF-B196-4131D0816F49Q55212538-0A825432-56D9-4744-A974-1B336CF41577Q55218109-F7E0568A-869F-4882-B404-323CF86FBF29Q55223377-1EDF5D56-65A8-4AAF-B182-ED237C4EA7C2Q55379857-DA637C41-E5CB-40A6-85CD-23091B9BCE5DQ55395700-B2841BE4-33BE-4A54-B502-047954FDE85BQ55514100-D3AB1BF5-C7BA-44FE-8A69-743A0BAD005FQ56395991-4CF40AA6-DF04-4E08-8CB0-7C6C691C772FQ57066931-4245AD34-9563-4AD0-A7B2-CECBDB0F1DB4
P2860
Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Effectiveness of Ledipasvir-So ...... Sustained Virologic Response.
@en
Effectiveness of Ledipasvir-So ...... Sustained Virologic Response.
@nl
type
label
Effectiveness of Ledipasvir-So ...... Sustained Virologic Response.
@en
Effectiveness of Ledipasvir-So ...... Sustained Virologic Response.
@nl
prefLabel
Effectiveness of Ledipasvir-So ...... Sustained Virologic Response.
@en
Effectiveness of Ledipasvir-So ...... Sustained Virologic Response.
@nl
P2093
P2860
P921
P1433
P1476
Effectiveness of Ledipasvir-So ...... Sustained Virologic Response.
@en
P2093
Alexander Kuo
Anna S Lok
David R Nelson
HCV-TARGET Study Group
Joseph K Lim
Lucy Akushevich
Lynn M Frazier
Mark S Sulkowski
Michael W Fried
Mitchell L Shiffman
P2860
P304
1131-1140.e5
P356
10.1053/J.GASTRO.2016.08.004
P407
P577
2016-08-23T00:00:00Z